Skip to main content
TNXP
NASDAQ Life Sciences

Tonix Pharma Doses First Patient in Phase 1 Migraine Study for TNX-1900

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$14.9
Mkt Cap
$201.081M
52W Low
$13.07
52W High
$69.97
52W Position info
14% above low
Off High info
79% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TNXP is trading near its 52-week low of $13.07 (14% above the low).

Summary

Tonix Pharmaceuticals announced the dosing of the first participant in a Phase 1 investigator-initiated study for TNX-1900, a potential treatment for migraine and craniofacial pain.


Key Events · Product Development and Regulatory · TNXP

  • Phase 1 Study Initiated for TNX-1900

    The first participant was dosed in an investigator-initiated Phase 1 study evaluating TNX-1900 (intranasal potentiated oxytocin) for trigeminal nerve-mediated vasodilation, a model for migraine and craniofacial pain.

  • Addresses Large Market with Novel Mechanism

    TNX-1900 aims to treat migraine and craniofacial pain by blocking CGRP release via oxytocin receptors, a distinct pathway from existing CGRP inhibitors.

  • Progress Amidst Financial Challenges

    This clinical advancement follows the company's recent 10-K filing which included a going concern warning and a proposed reverse stock split to maintain NASDAQ listing.


Analysis · TNXP · Life Sciences

This early-stage clinical milestone provides a positive development for Tonix Pharmaceuticals, which recently disclosed a "going concern" warning and is seeking a reverse stock split to avoid delisting. The initiation of a Phase 1 investigator-initiated study for TNX-1900, targeting migraine with a distinct mechanism, demonstrates continued pipeline execution despite significant financial challenges. While early, this progress is crucial for a biotechnology company facing existential risks, offering a potential path to future value creation.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNXP was trading at $14.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.1M. The 52-week trading range was $13.07 to $69.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNXP - Latest Insights

TNXP
Nov 13, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $2.38 info
Change: -$0.610 (-20%) info
Market Cap: $46.247M info
TNXP
Nov 09, 2026, 8:25 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $2.38 info
Change: -$1.62 (-41%) info
Market Cap: $46.247M info
TNXP
Nov 09, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $2.38 info
Change: -$1.72 (-42%) info
Market Cap: $46.247M info
TNXP
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $2.38 info
Change: -$1.97 (-45%) info
Market Cap: $46.247M info
TNXP
Oct 27, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.36
Real-time Price: $2.38 info
Change: -$2.98 (-56%) info
Market Cap: $46.247M info